Stoke Therapeutics:关键III期数据预计2027年第三季度揭晓,新药申请拟于下半年提交

美股速递
Jun 30

生物技术公司 Stoke Therapeutics 近日披露了其研发管线的重要时间表。备受关注的关键性III期临床试验数据,预计将于2027年第三季度获得最终结果。紧随其后,公司计划在2027年下半年完成向监管机构提交新药上市申请(NDA)的工作。

这一进展标志着该公司在研疗法向商业化迈出了关键一步。市场分析人士普遍关注该时间节点的数据表现,因其将直接影响该疗法的获批前景及公司未来的市场估值。投资者将密切关注后续进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10